BLGO BioLargo

BioLargo, Inc.’s CEO Discusses Business Milestones and FDA Progress with Uptick Newswire’s Stock Day Podcast

BioLargo, Inc.’s CEO Discusses Business Milestones and FDA Progress with Uptick Newswire’s Stock Day Podcast

PHOENIX, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Dennis Calvert, CEO of BioLargo, Inc. (OTCQB:), recently spoke with Stock Day Podcast’s Everett Jolly to update listeners on the company’s recent milestones.

Jolly started out the interview highlighting that BioLargo’s odor and VOC control products are set to do over $1 million in revenue in 2018.

“We launched the product about two years ago into the municipal waste handling industry,” Calvert explains to Uptick. “It took us about a year to get our foothold in the market and over the past six months, we signed national purchasing agreements with four of the top municipal waste handling companies in the country and have enjoyed 100% regional adoption with those accounts in Southern California, so the market is finally catching on that ours is a great product backed by great service. We are also servicing early adopters in the waste water treatment industry and new industries are just getting started as well. We have also transitioned from being a tech shop to a solutions provider, adding engineering, system design, installation, maintenance and service. We have only scratched the surface of the global opportunity for CupriDyne Clean.”

Jolly then shifted the interview to talk about Clyra Medical Technologies, Inc., the BioLargo subsidiary that uses innovative patent protected chemistry in advanced wound care. Calvert discussed the progress of its advanced wound care products under its subsidiary Clyra Medical Technologies, and its recent 510 (k) application with the FDA.

In a follow-up to the interview, Calvert expanded on their recent trip to Washington, DC to meet with the FDA about the company’s pending application. “In our meeting with FDA representatives last week, we were able to clarify the data requirements and the appropriate pathway to success for our application. The first series of questions asked of our team relates to labeling, shelf-life, and composition, and we think that request and the answers are straight forward. The more important request they made was that we conduct a short-term live animal study which requires a small period of work and money to accomplish. We believe the time frame to meet these requests is manageable within the next few months, and that the outcome will ultimately result in FDA clearance of the product.”

Jolly also asked Dennis about BioLargo Water’s AOS (Advanced Oxidation System), which is a technological breakthrough in water and wastewater treatment and has the potential to provide effective and cost-efficient elimination of pathogens and hard-to-treat organics from wastewater. Calvert said the product is nearing commercialization and is even currently part of several pre-commercial pilot projects in real world industrial settings. He also went on to explain the exciting independent 3rd-party validation of the high-value use of the AOS for managing micropollutants and other hard-to-treat contaminants for the wastewater industry.

“We have major projects that all focus on taking the system into the field to work with real clients to prove out its real economic value,” Calvert explained. “It’s the final piece of making that technology ready for market. We think it’s pretty exciting.”

To hear the entire interview with Dennis Calvert, click the Stock Day podcast link ().

About BioLargo, Inc.

BioLargo, Inc. is an innovative technology developer and environmental engineering company driven by a mission to "make life better" by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. We develop and commercialize disruptive technologies by providing the capital, support, and expertise to expedite them from "cradle" to "maturity" (). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (). Our industrial odor control division, Odor-No-More () features CupriDyne Clean Industrial Odor Eliminator (), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water () develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. Our subsidiary Clyra Medical () features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Contact Information:

Dennis Calvert President and CEO BioLargo, Inc. 949-643-9540 x2

Safe Harbor Act

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

About Uptick Newswire and the “Stock Day” Podcast

Founded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both national and international media outlets. Uptick is the sole producer of its “Stock Day” Podcast, which is the number one radio show of its kind in America. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire, which recently launched its Video Interview Studio located in Phoenix, Arizona.

Investors Hangout is a proud sponsor of “Stock Day,” and Uptick Newswire encourages listeners to visit the company’s message board at

SOURCE:

Uptick Newswire

 

EN
05/11/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioLargo

Sean Conroy
  • Sean Conroy

BioLargo - Firing on all cylinders

BioLargo reported $666,000 in total Q320 sales (+24.7% y-o-y), a new record, a $1.9m operating loss (flat year-on-year) and a $2.39m net loss (from $3.89m in Q319). It had $356,000 in Q320 sales from ONM Environmental, down 10% from Q319, but the division recovered significantly since the start of the pandemic (up 19% from Q120). Sequentially, companywide revenue growth was up 56% over Q220, a strong bounce back from COVID-19 disruptions, and total sales are up 15% for 9M20 to $1.52m. BioLargo a...

Sean Conroy
  • Sean Conroy

BioLargo - Clyraguard to be a major growth driver

BioLargo stated that it expects Clyra Medical (of which it owns a 48% interest) and its Clyraguard product to be a major driver of growth in the coming periods. Clyra Medical signed an agreement with a major national distributor in July, with the first substantial sales to occur in Q320. Clyra Medical reported a small revenue ($21,000) for Q220, reflecting one week of sales from a previous test marketing run.

 PRESS RELEASE

Dennis P. Calvert, President & CEO of BioLargo, Inc. Provides Key Upda...

Dennis P. Calvert, President & CEO of BioLargo, Inc. Provides Key Updates and Outlook in a New Audio Interview with SmallCapVoice.com AUSTIN, Texas, June 08, 2020 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (SCV) and BioLargo, Inc. (OTCQB:BLGO)(“the Company”), developer of sustainable technologies and a full-service environmental engineering company, today announced that a new audio interview with the Company is now available. The interview featuring an overview of BLGO’s current news and moves can be heard at . Dennis P. Calvert, President & CEO of BioLargo, discussed the Company’s bu...

Sean Conroy
  • Sean Conroy

BioLargo - Clyra launches Clyraguard

Clyra Medical, BioLargo’s partially owned (36%) subsidiary, recently announced that it registered with the FDA and launched Clyraguard, a disinfectant marketed for the treatment of non-critical surfaces such as personal protective equipment (PPE) that is non-irritating to skin. Concurrent with this BioLargo announced the results of two studies that showed Clyraguard and the company’s environmental product CupriDyne could both fully inactivate COVID-19.

Sean Conroy
  • Sean Conroy

BioLargo - A record-setting year

BioLargo reported record revenue of $1.86m for 2019, a 36% increase over 2018 and a record single quarter revenue of over $560,000 for Q4. Odor-no-More (ONM) had its best year to date with $1.46m in revenue ($832,000 gross profit). However, ONM fell short of its goal of breaking even for the year with a loss of $337,000 (albeit improved from the 2018 $433,000 loss) due to increased headcount for future growth. The company noted that in 2020 it will focus on increasing sales through improved dist...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch